Joey Mattingly, PharmD, MBA

In this series, we have used the recent announcement by CVS Health regarding a strategy to lower drug prices as an example to review basic pharmacoeconomic principles. For Part 3, we are going to discuss various stakeholders and how each might view the results of decisions based off of pharmacoeconomic analyses.

This series of pharmacoeconomics posts will explore the meaning of $100,000/quality-adjusted life year (QALY) and why it might matter to these 4 P’s: patients, payers, providers, and pharma. Part 2 puts ICER into context so it can be applied to decision-making.

This series of pharmacoeconomics posts will explore the meaning of $100,000/quality-adjusted life year (QALY) and why it might matter to these 4 P’s: patients, payers, providers, and pharma. Part 1 focuses on definitions and a basic calculation.